DexCom (DXCM) Stock Forecast & Price Target

$68.61

-0.44 (-0.64%)

(As of 09/6/2024 ET)

DexCom - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy
Based on 18 Analyst Ratings

Based on 18 Wall Street analysts who have issued ratings for DexCom in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 18 analysts, 6 have given a hold rating, 11 have given a buy rating, and 1 has given a strong buy rating for DXCM.

Consensus Price Target

$112.25
63.61% Upside

High Forecast	$161.00
Average Forecast	$112.25
Low Forecast	$75.00

According to the 18 analysts' twelve-month price targets for DexCom, the average price target is $112.25. The highest price target for DXCM is $161.00, while the lowest price target for DXCM is $75.00. The average price target represents a forecasted upside of 63.61% from the current price of $68.61.

Type	Current Forecast 9/8/23 to 9/7/24	1 Month Ago 8/9/23 to 8/8/24	3 Months Ago 6/10/23 to 6/9/24	1 Year Ago 9/8/22 to 9/8/23
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	11 Buy rating(s)	11 Buy rating(s)	11 Buy rating(s)	11 Buy rating(s)
Hold	6 Hold rating(s)	6 Hold rating(s)	3 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$112.25	$111.63	$140.94	$137.75
Forecasted Upside	63.61% Upside	28.71% Upside	18.71% Upside	17.07% Upside

Get DexCom Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for DXCM and its competitors with MarketBeat's FREE daily newsletter.

Ad WealthPress

This new buy indicator has the internet shook.

In the last few weeks we’ve seen countless people talking about a totally new stock indicator called Platform X… It identifies the markets strongest stocks, then delivers customized buy signals for those stocks… Even as the market stalled out it nailed several calls including a 100%+ winner on Newmont mining… At first we thought this was some sort of hocus pocus indicator… But it turned out to be a very viable tool for trading today’s market action… Which is the reason for today's email…

To check it out, just follow this link here.

DXCM Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

DXCM Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

DexCom Stock vs. The Competition

Type	DexCom	Medical Companies	S&P 500
Consensus Rating Score	2.72	2.77	2.51
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	63.61% Upside	1,207.55% Upside	11.35% Upside
News Sentiment Rating	Neutral News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
8/26/2024	Piper Sandler 2 of 5 stars		Reiterated Rating	Overweight ➝ Overweight	$90.00 ➝ $90.00	+20.74%
8/23/2024	Stifel Nicolaus 4 of 5 stars		Boost Target	Buy ➝ Buy	$90.00 ➝ $100.00	+38.35%
8/5/2024	Robert W. Baird 2 of 5 stars		Boost Target	Neutral ➝ Neutral	$80.00 ➝ $82.00	+13.42%
7/29/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$138.00 ➝ $113.00	+67.33%
7/26/2024	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Johnson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/26/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$156.00 ➝ $120.00	+88.62%
Get the Latest News and Ratings for DXCM and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for DexCom and its competitors with MarketBeat's FREE daily newsletter.
7/26/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$120.00 ➝ $75.00	+19.73%
7/26/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$163.00 ➝ $95.00	+49.42%
7/26/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$150.00 ➝ $115.00	+80.87%
7/26/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$165.00 ➝ $145.00	+125.82%
7/26/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$145.00 ➝ $80.00	-25.82%
7/26/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Overweight ➝ Neutral	$145.00 ➝ $75.00	-30.46%
7/23/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$145.00 ➝ $145.00	+29.87%
5/30/2024	Redburn Atlantic Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Neutral	$130.00	+1.85%
4/26/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Strong-Buy ➝ Strong-Buy	$151.00 ➝ $160.00	+25.38%
4/3/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$148.00 ➝ $161.00	+15.86%
10/16/2023	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Kratky Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
10/16/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$110.00	+37.81%
2/10/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$114.00 ➝ $125.00	+16.56%
1/26/2023	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$121.00	+16.35%
10/28/2022	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$85.00 ➝ $114.00	-0.81%
10/12/2022	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$125.00	+25.40%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 11:15 PM ET.

DXCM Forecast - Frequently Asked Questions

What is DexCom's forecast for 2024?: According to the research reports of 18 Wall Street equities research analysts, the average twelve-month stock price forecast for DexCom is $112.25, with a high forecast of $161.00 and a low forecast of $75.00.
Should I buy or sell DexCom stock right now?: 18 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last twelve months. There are currently 6 hold ratings, 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" DXCM shares.
Does DexCom's stock price have much upside?: According to analysts, DexCom's stock has a predicted upside of 27.77% based on their 12-month stock forecasts.
Has DexCom been downgraded by Wall Street analysts recently?: Over the previous 90 days, DexCom's stock had 3 downgrades by analysts.
What analysts cover DexCom?: DexCom has been rated by research analysts at Baird R W, Barclays, BTIG Research, Canaccord Genuity Group, JPMorgan Chase & Co., Morgan Stanley, Oppenheimer, Piper Sandler, Robert W. Baird, Royal Bank of Canada, Stifel Nicolaus, UBS Group, and Wells Fargo & Company in the past 90 days.
Do Wall Street analysts like DexCom more than its competitors?: Analysts like DexCom less than other "medical" companies. The consensus rating score for DexCom is 2.72 while the average consensus rating score for "medical" companies is 2.77. Learn more on how DXCM compares to other companies.